A Study of LY2801653 in Advanced Cancer

Inclusion Criteria

• •Part A- Diagnosed with advanced and/or metastatic cancer during dose escalation
• •Part B- Diagnosed with adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver with metastasis, or cholangiocarcinoma
• •Part C - Diagnosed with head and neck squamous cell carcinoma and have received at least one prior platinum-based systemic therapy
• •Part D - Diagnosed with cholangiocarcinoma and have not received more than 1 prior systemic therapy
• •Part E - Diagnosed with cholangiocarcinoma, either intrahepatic or extrahepatic, that is unresectable, recurrent, or metastatic. Participants must not have received prior systemic front line therapy for metastatic or resectable disease (i.e. participants may have received adjuvant gemcitabine but have not yet received gemcitabine/cisplatin for recurrent metastatic disease). Participants must be, in the opinion of the investigator, an appropriate candidate for experimental therapy. Participants should be evaluated for the need to undergo biliary drainage by stent placement prior to study participation. Participants should have adequate biliary drainage with no unresolved biliary obstruction.
• •Must be at least 18 years of age
• •Adequate hematologic, renal, and liver functions
• •Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
• •Ability to swallow capsules, with the exception of head and neck squamous cell carcinoma participants who may have study drug crushed and administered through a feeding tube